Recent Updates
Recently added Catalysts

i.v. Hydrocortisone

Phase 1

Adrenal Insufficiency | Small molecule | Endocrine |Neurocrine Biosciences, Inc.|Last Updated: Apr 26, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment14
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01960530An Investigational Study of HydrocortisonePHASE1 COMPLETED 14Oct 1, 2013Nov 1, 2014Apr 26, 20221 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Maximum Serum Concentration (Cmax)
Hourly from 0 to 24 hours

Derived PK for Serum Cortisol: Maximum serum concentration (Cmax)

AUC0-t
Hourly from 0 to 24 hours

Derived PK for Serum Cortisol: Area under the curve from 0-24 hours

Secondary Endpoints
Adverse Events (AEs)
Days 1-2 during each Study Period
Concentrations of Cortisol Binding Protein
Blood samples on Day 1 and/or Day 2 of each Study Period
Insulin Sensitivity Under Physiological Conditions and After Administration of Dexamethasone and Infacort®, Hydrocortisone Tablets and i.v Hydrocortisone.
Blood samples on Day 1 and/or Day 2 of each Study Period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
Endogenous CortisolNO_INTERVENTIONNo Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
DexamethasoneOTHER1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
Infacort®EXPERIMENTAL20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
Hydrocortisone TabletACTIVE_COMPARATOR20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
i.v Hydrocortisone InjectionACTIVE_COMPARATOR20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
Interventions
NameTypeDescription
Hydrocortisone granulesDRUGMulti-particulate granules
Hydrocortisone TabletDRUGStandard hydrocortisone tablets
i.v. Hydrocortisone InjectionDRUGStandard hydrocortisone solution for intravenous injection
DexamethasoneOTHERChallenge agent
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male volunteers between 18 and 60 years of age, inclusive (at screening). * Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))\*2. * Subjects with no clinically significant abnormal serum biochemistry, haematology and urin...

Countries:United Kingdom
Unlock Eligibility Criteria